Heat shock protein 70 (HSP70) expression in antimony susceptible/resistant clinical isolates of Leishmania donovani
DOI:
https://doi.org/10.3126/njb.v3i1.14225Keywords:
Pentavalent antimony, HSP70, visceral leishmaniasis, drug resistance, PFGE, hybridizationAbstract
Pentavalent antimonials have long been the first line of defence against leishmaniasis, but resistance has been reported in different parts of the world. Pentavalent antimony is reduced into trivalent form in the cells and is a potential inducer of HSP70 in L. donovani. Expression profile of HSP70 in antimony susceptible and resistant L. donovani isolates were characterized by Southern blot, Northern blot and western blot analysis. HSP70 gene copy number, gene expression and HSP70 protein expression was found uniform in both antimony sensitive and resistant clinical isolates. In laboratory condition, Leishmania cells respond to antimonial drug stress by three fold over expression of the HSP70 protein. The observed results indicated that HSP70 play important role in stress tolerance against antimonial drug without differential expression in antimony sensitive and resistance clinical isolates of L. donovani.
Nepal Journal of Biotechnology. Dec. 2015 Vol. 3, No. 1: 22-28
Downloads
1155
916
Downloads
Published
How to Cite
Issue
Section
License
Copyright Notice:
The manuscript submitted to NJB must be an original contribution, not previously published and should not be under consideration for publication elsewhere. When the manuscript is accepted for publication, the authors agree to automatically transfer the copyright of the article to the publisher. It should grant permission to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the NJB copyright and license agreement.
Authors transfer copyright to the publisher as part of a journal publishing agreement but have the rights to: Share their article for Personal Use, Internal Institutional Use and Scholarly Sharing purposes, with the NJB applies the Creative Commons Attribution-NonCommercial CC BY-NC license to all the works we publish after Jun 2020 (Before it was CC BY-NC-ND). Under this license, authors agree to make articles legally available for reuse, without permission or fees, for virtually any non-commercial purpose. Anyone may remix, adapt, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms. More details on CC BY-NC refer to its Licence Deed and Legal Code.
